United Therapeutics Corporation has a total of 1017 patents globally, out of which 494 have been granted. Of these 1017 patents, more than 57% patents are active. The United States of America is where United Therapeutics Corporation has filed the maximum number of patents, followed by Japan and Europe. Parallelly, United States of America seems to be the main focused R&D center and also is the origin country of United Therapeutics Corporation.
United Therapeutics Corporation was founded in 1996 by Martine A. Rothblatt. United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company’s lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously. As of August 2022, United Therapeutics Corporation has a market cap of $10.31 Billion.
Do read about some of the most popular patents of United Therapeutics Corporation which have been covered by us in this article and also you can find United Therapeutics Corporation patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over United Therapeutics Corporation patent portfolio.
How many patents does the Founder and CEO of United Therapeutics Corporation have?
The Founder and CEO Martine A. Rothblatt have 85 patents.
How many patents does United Therapeutics Corporation have?
United Therapeutics Corporation has a total of 1017 patents globally. These patents belong to 172 unique patent families. Out of 1017 patents, 582 patents are active.
How Many Patents did United Therapeutics Corporation File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | United Therapeutics Applications Filed | United Therapeutics Patents Granted |
| 2011 | 46 | 15 |
| 2012 | 48 | 16 |
| 2013 | 50 | 22 |
| 2014 | 67 | 35 |
| 2015 | 74 | 43 |
| 2016 | 31 | 35 |
| 2017 | 56 | 36 |
| 2018 | 50 | 61 |
| 2019 | 50 | 46 |
| 2020 | 41 | 35 |
| 2021 | 33 | 36 |
| 2022 | 11 | 27 |
Which United Therapeutics Corporation Drug Patents are Expiring in the Next 10 Years?
The patent no. US7999007B2 which is expiring in Mar, 2029, describing injecting an active agent in a pharmaceutical preparation is designed to kill gram-negative bacteria and hinder the growth of gram-positive bacteria. The injection involves using a buffer with a pH above about 10 or below about 4.5 and low buffer capacity. It’s important to note that the pharmaceutical preparation does not solely contain epoprostenol sodium as the active agent.
Given below is the list of few drugs patented by United Therapeutics Corporation accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.
| Drug Name | Patent Number | Patent Title | Patent Expiration |
| Remodulin | US7999007B2 | Buffer solutions having selective… | Mar, 2029 |
| Tyvaso | US11826327B2 | Treatment for interstitial lung disease | Jan, 2042 |
| Tyvaso Dpi | US10716793B2 | Treprostinil administration… | May, 2027 |
Interested in knowing about United Therapeutics Drug Patents Expiring in the next 10 years?
How many United Therapeutics Corporation patents are Alive/Dead?
Worldwide Patents
How Many Patents did United Therapeutics Corporation File in Different Countries?
Countries in which United Therapeutics Corporation Filed Patents
| Country | Patents |
| United States Of America | 224 |
| Japan | 102 |
| Europe | 101 |
| China | 85 |
| Canada | 77 |
| Korea (South) | 63 |
| Spain | 55 |
| Germany | 55 |
| India | 54 |
| Australia | 44 |
| Israel | 19 |
| Austria | 13 |
| New Zealand | 11 |
| Hong Kong (S.A.R.) | 8 |
| Denmark | 7 |
| Portugal | 5 |
| Mexico | 1 |
| Singapore | 1 |
| Brazil | 1 |
| Poland | 1 |
| Taiwan | 1 |
Where are Research Centers of United Therapeutics Corporation Patents Located?
10 Best United Therapeutics Corporation Patents
US6521212B1 is the most popular patent in the United Therapeutics Corporation portfolio. It has received 185 citations so far from companies like Insmed Incorporated, Nexien Biopharma Inc, and Respira Therapeutics Inc.
Below is the list of 10 most cited patents of United Therapeutics Corporation:
| Publication Number | Citation Count |
| US6521212B1 | 185 |
| US7417070B2 | 175 |
| US6441245B1 | 161 |
| US7384978B2 | 160 |
| US6756033B2 | 154 |
| US6809223B2 | 153 |
| US6700025B2 | 147 |
| US20080200449A1 | 140 |
| US6528688B2 | 139 |
| US7199157B2 | 137 |
What Percentage of United Therapeutics Corporation US Patent Applications were Granted?
United Therapeutics Corporation (Excluding its subsidiaries) has filed 135 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 67 have been granted leading to a grant rate of 65.05%.
Below are the key stats of United Therapeutics Corporation patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for United Therapeutics Corporation?
| Law Firm | Total Applications | Success Rate |
| Foley & Lardner Llp | 95 | 63.77% |
| Ropes & Gray Llp | 12 | 50.00% |
| Allen R Kipnes | 5 | 66.67% |
| Fish & Richardson Pc | 3 | 100.00% |
| Morse Barnes Brown & Pendleton Pc | 2 | 100.00% |
| Mr Nick C Bassil | 2 | 0.00% |
| Pillsbury Winthrop Shaw Pittman Llp | 2 | 50.00% |
| Sterne Kessler Goldstein & Fox Pllc | 2 | 100.00% |
| Verrill | 2 | 0% |
| Widerman Malek Pl | 2 | 100.00% |
EXCLUSIVE INSIGHTS COMING SOON!